A 32-year-old woman presents to the clinic with a 6-month history of progressive hypertension (BP 165/105 mmHg), episodic severe headaches, and profuse sweating. Her 24-hour urinary metanephrines are markedly elevated at 2.8 times the upper limit of normal. Imaging reveals a 3 cm right adrenal mass. On further evaluation, she is found to have a serum calcitonin of 285 pg/mL (normal <10) with a normal serum calcium. Thyroid ultrasound shows a hypoechoic nodule. Her 28-year-old brother was recently diagnosed with medullary thyroid cancer. Genetic testing reveals a RET proto-oncogene mutation (codon 634). Which of the following is the most appropriate next step in management?

Explanation

## Diagnosis and Management: MEN 2A Syndrome with Pheochromocytoma ### Clinical Presentation Analysis This patient has MEN 2A syndrome with: 1. **Medullary thyroid carcinoma (MTC)** — elevated calcitonin (285 pg/mL), thyroid nodule, family history of MTC 2. **Pheochromocytoma** — hypertension, episodic headaches, sweating, elevated urinary metanephrines, adrenal mass 3. **RET mutation at codon 634** — pathognomonic for MEN 2A (codon 634 mutations are associated with the highest risk of aggressive MTC and pheochromocytoma) ### Key Pathophysiology **Key Point:** MEN 2A is an autosomal dominant syndrome caused by activating mutations in the RET proto-oncogene (chromosome 10q11). RET mutations lead to constitutive activation of receptor tyrosine kinase signaling, causing C-cell hyperplasia and medullary thyroid carcinoma, adrenomedullary hyperplasia and pheochromocytoma, and parathyroid adenomas. **High-Yield:** RET codon 634 mutations are **high-risk** for aggressive MTC and carry an extremely high penetrance (>95%) for MTC by age 50. Prophylactic thyroidectomy is recommended in childhood (before age 5–10) for codon 634 mutations. ### Correct Management Sequence **Clinical Pearl:** The critical principle in MEN 2A management is to treat the pheochromocytoma BEFORE the thyroid cancer. Failure to do so risks a **catecholamine storm** during thyroid surgery, which can precipitate hypertensive crisis, arrhythmia, and death. ### Step-by-Step Management Protocol ```mermaid flowchart TD A["MEN 2A with Pheochromocytoma + MTC"]:::outcome A --> B["Step 1: Alpha-blockade<br/>(phenoxybenzamine or doxazosin)<br/>Goal: BP control, symptom relief"]:::action B --> C["Step 2: Beta-blockade<br/>(after alpha-blockade established)<br/>Prevent tachycardia & arrhythmias"]:::action C --> D["Step 3: Pheochromocytoma resection<br/>Laparoscopic adrenalectomy"]:::action D --> E["Step 4: Thyroidectomy with<br/>central lymph node dissection"]:::action E --> F["Outcome: Cure of pheochromocytoma;<br/>MTC managed surgically"]:::outcome ``` ### Pharmacological Blockade Details | Agent | Class | Mechanism | Timing | Endpoint | | --- | --- | --- | --- | --- | | **Phenoxybenzamine** | Non-selective α-blocker | Irreversible α1/α2 blockade | Start first | Orthostatic hypotension, BP <160/100 | | **Doxazosin** | Selective α1-blocker | Reversible α1 blockade | Alternative to phenoxybenzamine | Same as above | | **Propranolol / Atenolol** | β-blocker | β1/β2 blockade | Start AFTER α-blockade | HR 60–80 bpm, prevent reflex tachycardia | | **Nifedipine** | Calcium channel blocker | Vasodilation | Adjunct if needed | Additional BP control | **Warning:** NEVER start beta-blockade before alpha-blockade — unopposed alpha-adrenergic stimulation will cause severe hypertension and coronary vasospasm. ### Medullary Thyroid Cancer Management in MEN 2A **Mnemonic:** **"RET-MTC = Thyroidectomy + Lymph Node Dissection"** — Total thyroidectomy with central (level VI) lymph node dissection is the surgical standard for MTC in MEN 2A. 1. **Timing** — Perform thyroidectomy AFTER pheochromocytoma is resected and catecholamine excess is controlled 2. **Extent** — Total thyroidectomy (not lobectomy) because MTC is multifocal in MEN 2A 3. **Lymph node dissection** — Central compartment (level VI) dissection is standard; lateral neck dissection only if imaging shows lateral node involvement 4. **Postoperative surveillance** — Serum calcitonin and CEA monitoring; imaging (CT/MRI) for metastatic disease ### Why This Sequence Matters **High-Yield:** Intra-operative manipulation of a pheochromocytoma without prior alpha-blockade causes massive catecholamine release, leading to: - Severe hypertension (>250 mmHg) - Coronary vasospasm and myocardial ischemia - Arrhythmias (VF, SVT) - Stroke - Death Alpha-blockade expands intravascular volume and prevents these catastrophic events. ### Parathyroid Involvement in MEN 2A **Clinical Pearl:** Approximately 20–50% of MEN 2A patients develop primary hyperparathyroidism. This patient's serum calcium is normal, so parathyroid surgery is not indicated at this time, but biochemical screening (PTH, calcium) should be performed regularly.